Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Deborah Wexler MD, MSc

Deborah J. Wexler MD, MSc

Associate Professor of Medicine, Harvard Medical School; Chief, Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts

Dr. Deborah J. Wexler's research focuses on clinical effectiveness in type 2 diabetes. In addition, she is on the Editorial Board of Diabetes Care, and is a reviewer for multiple journals.

Disclosures

Dr. Wexler reports serving on Data Monitoring Committees for trials of oral semaglutide sponsored by Novo Nordisk.

Recent Contributions to PracticeUpdate:

  1. Impact of Neighborhoods on Diabetes Risk and Outcomes
  2. Food Insecurity and Diabetes
  3. Overview of Social Determinants of Health in the Development of Diabetes
  4. Imposter Syndrome: Diagnose Accurately Before Treating
  5. 2022 Top Story in Diabetes: Results of the GRADE Trial
  6. ADA 2022: Recommendations From Dr. Deborah Wexler
  7. 2021 Top Story in Diabetes: Empagliflozin for Heart Failure With Preserved Ejection Fraction
  8. Hemoglobin A1c Reduction and CV Risk Improvement: Correlation, Causation and Clinical Recommendations
  9. Rationale and Clinical Utility of Sulfonylureas in Contemporary Practice
  10. Comparative Effectiveness of a DPP-4 Inhibitor, a Sulfonylurea, a GLP-1 Agonist, and Basal Insulin: Data From the GRADE Trial

Elsewhere

Most Read This Week

Recently Updated